mAbxience (Fresenius Kabi majority-owned group with partial ownership from Insud Pharma) a global leader in biosimilar development and a key player in the Contract Development and Manufacturing Organization (CDMO) sector, together with Abdi İbrahim, the pharmaceutical industry leader in Türkiye, have announced today a significant technology transfer agreement. This collaboration marks a historic milestone in the production of biopharmaceuticals in Türkiye, specifically focusing on a crucial cancer drug.
Jurgen Van Broeck, Global Commercial Director of mAbxience, claimed, “This partnership with Abdi İbrahim is a testament to our commitment to extending our advanced biotechnological expertise globally. Our collaborative efforts in this technology transfer signify a major leap in biopharmaceutical production capabilities.”
Nezih Barut, Chairman of Abdi İbrahim, highlighted the importance of this agreement, stating, “This technology transfer is the first of its kind in Türkiye, involving a ‘cell-to-end product’ biotech pharmaceutical process. With AbdiBio, Türkiye’s largest biotech pharmaceutical manufacturing facility, we aim to make a significant impact. This step is vital in fulfilling our ambition to become a leader in the biotechnology field.”
The technology transfer enables the production of a drug used in treating metastatic colorectal cancer, cervical cancer, and glioblastoma multiforme amongst others. This undertaking is unprecedented in Türkiye’s biotechnology sector and involves the entire process from ‘cell-to-end product’, showcasing the production of monoclonal antibodies (mAbs) as a pioneering achievement. Abdi İbrahim is set to localize all stages of production of this bio-product, which plays a critical role in treatment.
“Through this technology transfer, we are localizing every phase of a biotechnology drug. This significantly reduces foreign dependency in pharmaceutical raw materials and drug substance, positively impacting the country’s economy,” added Barut.
mAbxience’s expertise in CDMO and its comprehensive capabilities, including cell line development, process development, and large-scale manufacturing, play a crucial role in this partnership. With GMP-approved facilities in Europe and South America, mAbxience is at the forefront of delivering integrated biomanufacturing solutions globally.
“We are excited to bring this level of innovation and self-sufficiency in biopharmaceuticals to Türkiye. This agreement is not just about technology transfer; it’s about shaping the future of global healthcare,” concluded Van Broeck.
mAbxience is a global Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals, supporting access to high-quality medicines. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi acquired a majority stake of mAbxience. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.
About Abdi İbrahim
Turkish pharmaceutical industry leader Abdi İbrahim’s journey of healing began in a small pharmacy store established in 1912 by the Pharmacist Abdi İbrahim Bey in Küçükmustafapaşa, Istanbul. Today, in addition to its partnerships with more than 30 licensing firms across the globe, Abdi İbrahim develops its own products and boasts the largest portfolio in the industry, with 250 brands and over 500 products. With its powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has held a leading position in the Turkish pharmaceutical industry since 2002. Today, Abdi İbrahim has subsidiaries operating in 17 countries outside Türkiye, exports to more than 70 countries from the European Union to Canada, North Africa to Asia, and generates the highest employment rate in the Turkish pharmaceutical industry with 5,500 qualified employees. Abdi İbrahim’s Esenyurt Production Complex in Istanbul houses the company’s R&D Centre, Chemical Products Production Facility, Türkiye’s largest biotechnological manufacturing facility AbdiBio, Hormone Production Facility, Sterile Ophthalmology & Sterile Inhalation Production Facility, and Chemical, Oncology, and Sterile Supplementary Production Facility. Abdi İbrahim also has R&D centers and production facilities in Kazakhstan and Algeria.